CONTROLLED SUBSTANCES ACT

Amendments

Drugs: improve DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and registration process for use of controlled substances in clinical trials (H.R. 639), S7494 [26OC], H8212 [16NO]

Bills and resolutions

Courts: clarify circumstances under which the enhanced penalty provisions for subsequent convictions apply (see H.R. 1254), H1609 [4MR]

Crime: enhance penalties for marketing candy-flavored controlled substances to minors (see S. 724), S1494 [12MR]

Dept. of Justice: exempt certain products from Controlled Substances Act requirements on scheduled listed chemicals if it is not practical to use such products in illicit manufacture of methamphetamine (see H.R. 3968), H8151 [5NO]

——— improve enforcement efforts relative to prescription drug diversion and abuse (see S. 483), S982 [12FE] (see H.R. 471), H530 [22JA]

——— make the Controlled Substances Act inapplicable to marijuana in States that have legalized marijuana and have State regulations in effect to protect certain Federal interests (see H.R. 3746), H6974 [9OC]

Drugs: address sentencing disparity between crack and powder cocaine (see H.R. 1255), H1609 [4MR]

——— clarify how synthetic drugs known as analogues are to be regulated (see H.R. 3537), H6136 [17SE]

——— decriminalize marijuana at the Federal level and leave States the power to regulate marijuana similar to the power to regulate alcohol (see H.R. 1013), H1084 [20FE]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, allow banks to work with medical marijuana businesses, enable medicinal research, and allow prescription to veterans (see S. 683), S1383 [10MR] (see H.R. 1538), H1847 [23MR]

——— establish a list of synthetic drugs known as analogues and prohibit most importation, amend sentencing for violations, and improve regulation relative to such analogues (see H.R. 4229), H9270 [10DE]

——— exclude cannabidiol and cannabidiol-rich plants from the definition of marijuana (see S. 1333), S2850 [13MY] (see H.R. 1635), H2033 [25MR]

——— exempt real property from civil forfeiture due to medical-marijuana-related conduct authorized by State law (see H.R. 262), H188 [9JA]

——— focus limited Federal resources on the most serious offenders by modifying sentencing guidelines for certain drug offenses (see S. 502), S983 [12FE]

——— improve DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and registration process for use of controlled substances in clinical trials (see S. 481), S982 [12FE] (see H.R. 639), H702 [2FE]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues (see S. 36), S11 [6JA] (see S. 1327), S2850 [13MY] (see H.R. 1186), H1499 [27FE]

——— increase access to opioid addiction treatment by expanding ability of medical professionals to provide medication-assisted therapies (see S. 1455), S3309 [22MY] (see H.R. 2536), H3560 [21MY]

——— modernize treatment of opioid addiction (see H.R. 2872), H4650 [24JN]

——— prohibit Federal prosecution of residents who are acting in accordance with their State’s marijuana laws (see H.R. 1940), H2415 [22AP]

——— provide for legitimate use of medicinal marijuana in accordance with State laws (see H.R. 2373), H3252 [15MY]

——— provide that Federal law shall not preempt State law governing marijuana (see H.R. 3629), H6306 [28SE]

——— reclassify certain low-level felonies as misdemeanors and eliminate increased penalties for cocaine offenses where the cocaine involved is cocaine base (see S. 1138), S2530 [29AP] (see H.R. 2153), H2768 [30AP]

——— reduce opioid misuse and abuse (see H.R. 3677), H6787 [1OC]

——— reschedule marijuana under the Controlled Substances Act, allow for medicinal use of marijuana in accordance with State laws, and exclude cannabidiol from the definition of marijuana (see H.R. 1774), H2209 [14AP]

Health care professionals: authorize physicians to transport controlled substances from a practice setting to another practice setting or disaster area (see H.R. 3014), H5029 [9JY]

——— require certain practitioners authorized to prescribe controlled substances to complete continuing education (see S. 1392), S3183 [20MY] (see H.R. 3889), H7623 [3NO]

Law enforcement: exclude industrial hemp from the definition of marijuana (see S. 134), S100 [8JA] (see H.R. 525), H581 [26JA]

Cost Estimates

Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639): CBO, H1641 [16MR]

Letters

Ensuring Patient Access and Effective Drug Enforcement Act: Representative Goodlatte, Committee on the Judiciary (House), H2330 [21AP]

——— Representative Upton, Committee on Energy and Commerce (House), H2330 [21AP]

Improving Regulatory Transparency for New Medical Therapies Act: Representative Goodlatte, Committee on the Judiciary (House), H1640 [16MR]

——— Representative Upton, Committee on Energy and Commerce (House), H1640 [16MR]

Remarks in House

DEA: prohibit funding to investigate physicians prescribing certain narcotic drugs for maintenance or detoxification treatment, H3734, H3735 [2JN]

Dept. of Justice: improve enforcement efforts relative to prescription drug diversion and abuse (H.R. 471), H2329–H2332 [21AP]

Drugs: decriminalize marijuana at the Federal level and leave States the power to regulate marijuana, H7031 [21OC], H8284 [18NO]

——— decriminalize marijuana at the Federal level and leave States the power to regulate marijuana similar to the power to regulate alcohol, H985 [12FE]

——— end Federal ban of medical marijuana, allow cultivation, allow importation of hemp, enable medicinal research, and reform Federal enforcement relative to State and local laws, H3584 [1JN]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, allow banks to work with medical marijuana businesses, enable medicinal research, and allow prescription to veterans (H.R. 1538), E385 [23MR]

——— exclude cannabidiol and cannabidiol-rich plants from the definition of marijuana (H.R. 1635), H8435 [30NO], H8656 [1DE]

——— focus limited Federal resources on the most serious offenders by modifying sentencing guidelines for certain drug offenses (H.R. 920), H3299 [18MY], E529 [20AP]

——— improve DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and registration process for use of controlled substances in clinical trials (H.R. 639), H1638–H1641 [16MR]

——— improve DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and registration process for use of controlled substances in clinical trials (H.R. 639), Senate amendment, H8212, H8213 [16NO]

——— increase access to opioid addiction treatment by expanding ability of medical professionals to provide medication-assisted therapies (H.R. 2536), H6845 [7OC]

——— prohibit Federal prosecution of residents who are acting in accordance with their State’s marijuana laws (H.R. 1940), H2414 [22AP], H2461 [23AP]

——— provide that Federal law shall not preempt State law governing marijuana, H6310 [29SE], H9028 [8DE]

Rosenberg, Chuck: question of fitness to serve as DEA Administrator relative to comments on medical marijuana, H8284 [18NO]

Remarks in Senate

Crime: enhance penalties for marketing candy-flavored controlled substances to minors (S. 724), S1496 [12MR]

Drugs: decriminalize marijuana at the Federal level and leave States the power to regulate marijuana similar to the power to regulate alcohol, S7620 [29OC]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, allow banks to work with medical marijuana businesses, enable medicinal research, and allow prescription to veterans (S. 683), S1385 [10MR]

——— focus limited Federal resources on the most serious offenders by modifying sentencing guidelines for certain drug offenses (S. 502), S962, S990–S992 [12FE], S1378–S1380 [10MR], S1576–S1580 [17MR]

——— improve DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and registration process for use of controlled substances in clinical trials (H.R. 639), S7495 [26OC]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues (S. 1327), S4337 [22JN]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues (S. 36), S19 [6JA]

Law enforcement: exclude industrial hemp from the definition of marijuana (S. 134), S102 [8JA], S3762 [4JN]

Reports filed

Ensuring Patient Access and Effective Drug Enforcement Act: Committee on Energy and Commerce (House) (H.R. 471) (H. Rept. 114–85), H2318 [20AP]

Improving Regulatory Transparency for New Medical Therapies Act: Committee on Energy and Commerce (House) (H.R. 639) (H. Rept. 114–41), H1660 [16MR]

——— Committee on Health, Education, Labor, and Pensions (Senate) (S. 481), S7101 [1OC]

Texts of

H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act, H2329 [21AP]

H.R. 639, Improving Regulatory Transparency for New Medical Therapies Act, H1638 [16MR], H8212 [16NO]

S. 134, Industrial Hemp Farming Act, S102 [8JA]